Cancer drug tested before surgery for non-invasive breast condition
NCT ID NCT03535506
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving the drug palbociclib before surgery could cause changes in breast tissue in people with ductal carcinoma in situ (DCIS), a very early form of breast cancer. It planned to enroll 24 participants, but was stopped early after only 17 joined. The main goal was to see if the approach was practical, not to prove it works as a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DCIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Medstar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One-Week radiation for breast cancer: MRI precision may cut side effects
- New test may help tailor treatment for early breast cancer
- New genetic test may help women with early breast cancer avoid unnecessary treatment
- One-Week radiation shows promise for breast cancer patients
- Could monitoring replace surgery for some breast lesions?
- Breast cancer overdiagnosis? landmark trial tests monitoring vs. surgery for Low-Risk DCIS